The Ministry of Health withdraws a vitamin that does not meet the specifications and allows the use of cholesterol-lowering drugs for pregnant women
The Ministry of Health and Community Protection decided to withdraw the medicinal product “Amerix Vitamin D3 50,000 IU” for not conforming to the approved specifications, and also removed the warning regarding the use of cholesterol-lowering statin drugs during pregnancy.
In a circular addressed to all health facilities and health care practitioners, the Ministry stated that the Ministry of Health and Community Protection had requested the manufacturer of the "Amerix Vitamin D3 50,000 IU" pill product, to withdraw the product from the public and private health sectors, while asking all health care practitioners not to use the product. mentioned, if any.
And it demanded all pharmacies to stop dispensing this product and return it to the supplier, noting that the decision to withdraw and other decisions related to the same product came after the Ministry's Quality Control Laboratory for Medical Products analyzed the product, and the results of the analyzes proved that the product did not conform to the approved specifications, and represented the average weight. and dissolution time and amount of vitamin D.
The ministry pointed out that the aforementioned product is registered with the ministry, calling on the public to report the side effects of the drug on the specified email, with its readiness to receive all inquiries related to the aforementioned product.
In another context, the Ministry announced the removal of the warning related to contraindications to the use of statin drugs that lower cholesterol for pregnant patients, noting that these drugs are registered with the Ministry and are safe to use and have not been withdrawn from the market.
The ministry informed all health facilities and health care practitioners that the US Food and Drug Administration lifted its previous warning not to use this type of medication for pregnant women.
The Ministry recommended that patients who are taking statin drugs should inform their healthcare professional when they are pregnant or suspected of being pregnant, so that the healthcare professional can provide the necessary recommendations regarding the use of statin drugs during pregnancy and lactation.
Patients at high risk of heart attack or stroke who need statins after delivery should not breastfeed and use alternatives such as infant formula.
The ministry called on health care practitioners to be careful when treating pregnant women with statin drugs and to avoid them unless necessary, after assessing the patient’s condition. The patient should be discussed with the patient about taking cholesterol medications (statins) while breastfeeding.
She stressed the need to reassure patients that cholesterol treatment drugs (statins) do not affect pregnancy in its beginning or before.
Follow our latest local and sports news and the latest political and economic developments via Google news